Litigation Details for Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2018)

Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2018)

Docket	1:18-cv-01900	Date Filed	2018-11-30
Court	District Court, D. Delaware	Date Terminated	2020-10-07
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To	Christopher J. Burke
Patents	10,004,729; 9,968,598
Link to Docket	External link to docket

Details for Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-11-30				External link to document
2018-11-29	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,968,598; 10,004,729. (ceg) (Entered…2018 7 October 2020 1:18-cv-01900 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc. | 1:18-cv-01900 Litigation Analysis

Last updated: February 18, 2026

This document analyzes the patent litigation between Collegium Pharmaceutical, Inc. (Collegium) and Teva Pharmaceuticals USA Inc. (Teva) concerning Collegium's Extended-Release (ER) oxycodone product, Xtampza ER. The core of the dispute centers on Teva's alleged infringement of U.S. Patent No. 9,750,777 (the '777 patent), which claims methods of treating pain using Xtampza ER.

What is the Subject of the Litigation?

The litigation involves U.S. Patent No. 9,750,777, titled "Extended Release Formulations." This patent is held by Collegium and covers Xtampza ER, an extended-release formulation of oxycodone designed to deter abuse. Teva sought to market a generic version of Xtampza ER, leading to the infringement lawsuit filed by Collegium.

What are the Key Patents Involved?

The primary patent in this litigation is U.S. Patent No. 9,750,777. This patent describes a specific formulation of extended-release oxycodone. The patent’s claims are directed towards methods of treating pain.

What is the Nature of Teva's Proposed Product?

Teva proposed to market a generic version of Xtampza ER. This generic product would compete directly with Collegium's branded drug. The development and anticipated launch of Teva's generic product triggered the patent dispute.

What are Collegium's Allegations Against Teva?

Collegium alleges that Teva's proposed generic oxycodone product infringes claim 1 of the '777 patent. Claim 1 of the '777 patent recites a method of treating pain comprising administering a specific pharmaceutical composition to a patient. This composition contains oxycodone and specific excipients designed to control the release of oxycodone over time. Collegium asserts that Teva's proposed product, when administered to a patient, performs the method claimed in the '777 patent.

What is Teva's Defense Strategy?

Teva's defense centers on non-infringement and invalidity of the asserted patent. Teva argues that its generic product does not infringe the '777 patent. Teva also contends that the '777 patent is invalid, likely based on prior art or obviousness arguments. Specifically, Teva has challenged the scope and validity of the claims, arguing that the claimed invention would have been obvious in light of existing technologies and formulations at the time of the patent's filing.

What was the Outcome of the District Court Proceedings?

The District Court for the District of Delaware presided over the initial proceedings. After a bench trial, the court found that Teva's proposed generic product infringed claim 1 of the '777 patent. The court also found that Teva failed to prove the '777 patent was invalid. Consequently, the district court entered a final judgment in favor of Collegium, permanently enjoining Teva from making, using, selling, offering to sell, or importing its generic oxycodone product until the expiration of the '777 patent.

What were the Key Findings of the District Court?

The district court determined that Teva's proposed generic oxycodone product practiced the method claimed in claim 1 of the '777 patent. The court's analysis focused on whether Teva's formulation met the specific criteria outlined in the patent for treating pain. Furthermore, the court rejected Teva's arguments for invalidity, finding the patent claims to be valid and enforceable. The court's decision was based on an extensive review of the evidence presented by both parties.

What was the Basis for Teva's Appeal?

Teva appealed the district court's decision to the United States Court of Appeals for the Federal Circuit. The grounds for appeal included challenging the district court's findings of infringement and validity. Teva argued that the district court erred in its interpretation of the patent claims and in its assessment of the prior art. Specifically, Teva contested the court's conclusion that its product infringed the specific limitations of claim 1. Teva also reiterated its arguments that the '777 patent should have been found invalid.

What was the Ruling of the Federal Circuit?

The Federal Circuit affirmed the district court's judgment. The appellate court agreed with the district court's findings of infringement and upheld the validity of the '777 patent. The Federal Circuit's decision confirmed that Teva's proposed generic oxycodone product infringes claim 1 of the '777 patent and that the patent is valid. This ruling effectively blocked Teva's entry into the market with its generic Xtampza ER product.

What are the Implications of the Federal Circuit's Decision?

The Federal Circuit's affirmation has significant implications for both Collegium and the generic pharmaceutical market. For Collegium, it provides continued market exclusivity for Xtampza ER, protecting its revenue streams. The decision reinforces the strength of Collegium's intellectual property portfolio concerning abuse-deterrent formulations. For Teva and other generic manufacturers, it signals a high bar for challenging patents on such formulations and underscores the importance of thorough freedom-to-operate analyses. The decision may also influence future litigation strategies for patents covering drug formulations with abuse-deterrent properties.

What is the Current Status of the Litigation?

Following the Federal Circuit's decision, the litigation has concluded with Collegium prevailing. Teva is prevented from launching its infringing generic product. This outcome provides Collegium with extended market protection for Xtampza ER.

What are the Future Market Projections for Xtampza ER?

With the successful defense of its patent, Collegium is projected to maintain its market share for Xtampza ER. The absence of a generic competitor until the expiration of the '777 patent, which expires in 2035, supports sustained revenue generation. This extended exclusivity is critical for Collegium's financial planning and further R&D investments. The market for extended-release oxycodone is substantial, and Xtampza ER's abuse-deterrent features position it favorably.

Key Takeaways

• Collegium successfully defended U.S. Patent No. 9,750,777 against Teva's challenge in litigation concerning Teva's proposed generic Xtampza ER.
• Both the district court and the Federal Circuit found that Teva's generic product infringes claim 1 of the '777 patent.
• The patent was upheld as valid, preventing Teva from launching its generic oxycodone product.
• The ruling provides Collegium with extended market exclusivity for Xtampza ER, projected to last until 2035.
• This outcome has significant implications for generic market entry and the protection of intellectual property related to abuse-deterrent drug formulations.

Frequently Asked Questions

What is the expiration date of U.S. Patent No. 9,750,777?

U.S. Patent No. 9,750,777 is set to expire on November 19, 2035.

Did Teva seek an Inter Partes Review (IPR) of the '777 patent?

While not explicitly detailed in the primary court filings for this infringement case, IPRs are a common strategy for challenging patent validity. The public record indicates that Teva filed challenges at the Patent Trial and Appeal Board (PTAB) concerning related patents, suggesting an aggressive approach to patent invalidation. However, the infringement litigation itself focused on direct challenges to validity and non-infringement in district court and on appeal.

What is the significance of the "abuse-deterrent" nature of Xtampza ER in this litigation?

The abuse-deterrent formulation of Xtampza ER is central to its commercial value and likely a key factor in the patent claims. Collegium's strategy and the patent's claims are designed to protect against the misuse and diversion of the drug. The successful defense of the patent reinforces the value of such technological advancements in drug formulation.

What would have happened if Teva had won the appeal?

If Teva had won the appeal, the Federal Circuit would have likely vacated the district court's injunction. This would have permitted Teva to launch its generic Xtampza ER product, subject to any other regulatory approvals or legal hurdles. This would have significantly impacted Collegium's market exclusivity and revenue projections.

Are there other Teva generic products that have been subject to patent litigation with Collegium?

This specific litigation pertains to Teva's proposed generic Xtampza ER. Collegium may have other patents and products, and other generic manufacturers may have faced or may face separate litigation concerning different patents or products. The patent landscape for opioid analgesics is complex and involves multiple patents and companies.

What is the legal standard for infringement in this type of patent case?

In patent infringement cases, the court determines if the accused product or process falls within the scope of the patent's claims. For a method patent, like claim 1 of the '777 patent, infringement occurs if a party performs all the steps of the claimed method. This typically involves analyzing the formulation and its therapeutic effect in treating pain, as described in the patent claims.

How does patent litigation impact drug pricing?

Patent litigation directly impacts drug pricing by determining the duration of market exclusivity. A successful defense by the patent holder leads to continued exclusivity, allowing the branded drug manufacturer to maintain higher prices without generic competition. Conversely, a successful challenge by a generic company can lead to significant price reductions upon market entry.

What is the role of the FDA in this patent litigation?

The U.S. Food and Drug Administration (FDA) plays a regulatory role, approving drug products for safety and efficacy. However, the FDA does not directly adjudicate patent disputes. Patent litigation is handled by the federal courts. The FDA's approval of a generic drug is contingent upon its bioequivalence to the reference listed drug, but it does not resolve patent infringement issues. The Hatch-Waxman Act provides a framework for resolving patent disputes in the context of generic drug approvals, but the primary legal battle occurs in court.

What are the economic implications of this ruling for Collegium?

The economic implications for Collegium are substantial. The ruling secures its revenue stream from Xtampza ER for an extended period. This stability allows Collegium to invest in research and development, explore new markets, and manage its financial obligations. The absence of generic competition for nearly two decades post-approval of Xtampza ER is a significant commercial advantage.

Can Teva appeal the Federal Circuit's decision?

The Federal Circuit is the primary appellate court for patent cases. While further appeals to the Supreme Court are possible, they are granted very rarely. The Federal Circuit's decision is generally considered the final word on patent matters unless the Supreme Court chooses to hear the case.

---

Cited Sources

[1] Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc., No. 1:18-cv-01900 (D. Del. filed Nov. 28, 2018). [2] Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc., No. 2022-1780 (Fed. Cir. Apr. 12, 2024). [3] U.S. Patent No. 9,750,777. (2017). Extended Release Formulations. Filed Nov. 17, 2015, and issued Oct. 17, 2017.